These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14994771)

  • 1. Sinus tissue concentration of moxifloxacin after a single oral dose.
    Dinis PB; Monteiro MC; Martins ML; Silva N; Morais JG
    Ann Otol Rhinol Laryngol; 2004 Feb; 113(2):142-6. PubMed ID: 14994771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus.
    Gehanno P; Darantière S; Dubreuil C; Chobaut JC; Bobin S; Pages JC; Renou G; Bobin F; Arvis P; Stass H
    J Antimicrob Chemother; 2002 May; 49(5):821-6. PubMed ID: 12003977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
    Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
    J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing.
    Gardner SY; Davis JL; Jones SL; LaFevers DH; Hoskins MS; McArver EM; Papich MG
    J Vet Pharmacol Ther; 2004 Feb; 27(1):57-60. PubMed ID: 14995968
    [No Abstract]   [Full Text] [Related]  

  • 5. Penetration and accumulation of moxifloxacin in uterine tissue.
    Stass H; Kubitza D; Aydeniz B; Wallwiener D; Halabi A; Gleiter C
    Int J Gynaecol Obstet; 2008 Aug; 102(2):132-6. PubMed ID: 18501909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin penetration into human gastrointestinal tissues.
    Wirtz M; Kleeff J; Swoboda S; Halaceli I; Geiss HK; Hoppe-Tichy T; Büchler MW; Friess H
    J Antimicrob Chemother; 2004 May; 53(5):875-7. PubMed ID: 15056642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration.
    Abd El-Aty AM; Goudah A; Shah SS; Shin HC; Shimoda M; Shim JH
    J Vet Pharmacol Ther; 2007 Dec; 30(6):586-91. PubMed ID: 17991229
    [No Abstract]   [Full Text] [Related]  

  • 8. Penetration of cefuroxime into chronically inflamed sinus mucosa.
    Dinis PB; Monteiro MC; Lobato R; Martins ML; Gomes A
    Laryngoscope; 1999 Nov; 109(11):1841-7. PubMed ID: 10569419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.
    Rink AD; Stass H; Delesen H; Kubitza D; Vestweber KH
    Clin Drug Investig; 2008; 28(2):71-9. PubMed ID: 18211115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
    Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
    J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose.
    Pea F; Marioni G; Pavan F; Staffieri C; Bottin R; Staffieri A; Furlanut M
    Pharmacol Res; 2007 Jan; 55(1):38-41. PubMed ID: 17092740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers.
    Kanjanawart S; Gaysonsiri D; Phunikom K; Simasathiansopon S; Tangsucharit P; Vannaprasaht S; Kaewkamson T; Tassaneeyakul W
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):249-54. PubMed ID: 23357835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreal penetration of oral moxifloxacin in humans.
    Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
    Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromelain's penetration into the blood and sinonasal mucosa in patients with chronic rhinosinusitis.
    Passali D; Passali GC; Bellussi LM; Sarafoleanu C; Loglisci M; Manea C; Iosif C; Passali FM
    Acta Otorhinolaryngol Ital; 2018 Jun; 38(3):225-228. PubMed ID: 29984799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
    Kees MG; Weber S; Kees F; Horbach T
    J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
    Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.